









Join this engaging session targeted to infectious disease specialists and HIV primary care physicians. With the quickly emerging medications in the Canadian HIV landscape, it is imperative for specialists and primary care physicians to continuously evaluate safety of therapies and HIV regimens, depending on each patient's history and circumstances. This program will walk you through case studies and will engage participants via voting in a modified script concordance format.

This session is a repeat of the hybrid session which was held in Vancouver on April 5. It has been extended to allow more time for discussion.

REGISTER NOW

By the end of the session, participants will be able to:

- Understand the safety profile of selected NRTI (TAF, TDF, ABC) and the impact of boosted vs. unboosted regimens on this profile.
- Critically evaluate the optimal NRTI regimens for specific patients and clinical contexts.
- Address the impact of genetic mutations and comorbidities on treatment decisions.

Date: Friday, June 3, 2022 **Time:** 12:00 - 13:30 EDT

Virtual login begins at 11:50

Virtual Registration

- · This session will be delivered in a virtual format.
- There is no fee to attend, however preregistration is required.
- · A Zoom link will be sent to you following registration.

CME Credits

- A certificate of attendance will be emailed to you following the session
- You may claim 1.5 hours of CME for the session





This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck and was planned to achieve scientific integrity, objectivity and balance.

MERCK You may claim a maximum of 1.5 hours of CME for this program.

Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.